LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

A study reports that people living in lower income neighborhoods were at a higher risk for hidradenitis suppurativa.

Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the launch of the second edition Health Equity ...

In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

The MoU was signed by H.E. Rashed Obaid Alsuwaidi - Director General, representing ADPHC, and Mohamed Ezz Eldin, Head of GCC, ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Greek use of interoperable digital tools and secure data platforms such as the EHDS could boost early detection and ...